Premier Alternatives

Sydnexis

Drug Discovery · Del Mar, CA · Founded 2014 · Privately Held (backing)

Developer of a eyecare medicine and drug designed to treat myopia. Sydnexis is based in Del Mar, CA and was founded in 2014. Its last reported valuation was $90 million in Aug 2021. It has raised $76.5 million across 4 recorded rounds; the latest was a $20 million early-stage round in Apr 2025.

Last reported valuation
$90.0M
Oct 2026
Priced at
—
Total raised
$76.5M
Last round
Early Stage VC
Apr 2025

Sydnexis key facts

as of Oct 2026
  • Developer of a eyecare medicine and drug designed to treat myopia.
  • Sydnexis is valued at approximately $90.0M as of Oct 2026 (last reported valuation).
  • It has raised $76.5M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Apr 2025.
  • Notable investors include RA Capital Management, Longitude Capital, Bluestem Capital Company, Medicxi, SC Master Fund — 6 tracked in total.
  • Sydnexis has filed 4 Form Ds with the SEC since 2017, most recently Apr 2025 ($20.0M sold to 23 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$90.0M

Sydnexis's last reported valuation, Aug 2021. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Sydnexis with a free account
  • ·Watch Sydnexis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Sydnexis funding rounds

4 rounds
Apr 2025Early Stage VC$20.0MSEC filing▮
Apr 2024Seed Round$1.0MSEC filing▮
Aug 2021Later Stage VC (Series B)$50.0M▮
Oct 2017Early Stage VC$5.5MSEC filing▮
Full funding history →

Sydnexis valuation

Sydnexis's last reported valuation was $90 million in Aug 2021. No priced round, secondary trade or fund mark has surfaced since.

How much has Sydnexis raised?

Sydnexis has raised $76.5 million across 4 recorded rounds since 2017. The largest was a $1 million seed round in Apr 2024; the most recent was a $20 million early-stage round in Apr 2025.

Sydnexis has filed 4 Form Ds with the SEC since 2017, most recently in Apr 2025 ($20 million sold to 23 investors).

Sydnexis investors

6 investors are on record for Sydnexis, including RA Capital Management, Longitude Capital, Bluestem Capital Company and Medicxi. The early-stage round in Apr 2025 drew 23 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Indapta Therapeutics ($90 million), Hyku Biosciences ($85 million) and Linnaeus Therapeutics ($83.1 million).

About Sydnexis

Developer of a eyecare medicine and drug designed to treat myopia. The company offers a topical eyedrop formulation used to treat the progression of myopia in children, enabling medical professionals and healthcare institutions to control and reduce the number of cases of eye disorders in children effectively.

Industry
Drug Discovery
Sector
Healthcare
HQ
Del Mar, CA, United States
Founded
2014
Employees
21
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.